- Home
- OGI vs ADAP Comparison
OGI vs ADAP Comparison
Compare OGI & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- ADAP
- Stock Information
- Founded
- OGI 2013
- ADAP 2008
- Country
- OGI Canada
- ADAP United Kingdom
- Employees
- OGI N/A
- ADAP N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- OGI Health Care
- ADAP Health Care
- Exchange
- OGI Nasdaq
- ADAP Nasdaq
- Market Cap
- OGI 155.2M
- ADAP 73.1M
- IPO Year
- OGI N/A
- ADAP 2015
- Fundamental
- Price
- OGI $1.11
- ADAP $0.30
- Analyst Decision
- OGI
- ADAP Strong Buy
- Analyst Count
- OGI 0
- ADAP 5
- Target Price
- OGI N/A
- ADAP $1.83
- AVG Volume (30 Days)
- OGI 369.3K
- ADAP 775.4K
- Earning Date
- OGI 05-12-2025
- ADAP 05-13-2025
- Dividend Yield
- OGI N/A
- ADAP N/A
- EPS Growth
- OGI N/A
- ADAP N/A
- EPS
- OGI N/A
- ADAP N/A
- Revenue
- OGI $115,451,336.00
- ADAP $178,032,000.00
- Revenue This Year
- OGI $50.30
- ADAP N/A
- Revenue Next Year
- OGI $16.01
- ADAP $69.81
- P/E Ratio
- OGI N/A
- ADAP N/A
- Revenue Growth
- OGI N/A
- ADAP 195.34
- 52 Week Low
- OGI $0.85
- ADAP $0.20
- 52 Week High
- OGI $2.11
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- OGI 52.29
- ADAP 53.92
- Support Level
- OGI $1.09
- ADAP $0.30
- Resistance Level
- OGI $1.20
- ADAP $0.32
- Average True Range (ATR)
- OGI 0.05
- ADAP 0.02
- MACD
- OGI 0.00
- ADAP 0.01
- Stochastic Oscillator
- OGI 55.00
- ADAP 77.22
About OGI Organigram Holdings Inc.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.